Elevai Labs Inc, a medical aesthetic company specializing in physician-dispensed skincare, announced it has signed an exclusive, worldwide manufacturing and processing technology licensing agreement with INmune Bio Inc. The licensing agreement grants Elevai a license to use INmune Bio’s proprietary “EMx” technology, developed by INmune Bio’s Chief Manufacturing Officer Mark Lowdell, PhD. This reportedly will allow Elevai to manufacture current Good Manufacturing Practice (cGMP) grade, human umbilical cord-derived mesenchymal stromal cells (hucMSCs) at a lower cost to Elevai than purchasing hucMSCs outright. Manufactured hucMSCs can be incorporated into certain licensed topical cosmetic products sold in the medical aesthetics skincare market.
In a press release from Elevai, it says it believes incorporating the EMx technology into its operations is a step towards the company’s goal of achieving vertical manufacturing integration, while also expanding long term production capabilities and lowering overall costs. Ultimately, Elevai says it believes controlling its processes through its product pipeline with what it believes to be efficient technologies like EMx will allow greater stem cell consistency, purity, and propel Elevai’s branded cosmetic products further to maintain the company’s position as an industry innovator in the medical aesthetics skincare market.
Jordan R. Plews, PhD, CEO of Elevai Labs Inc, said of the agreement, “Partnering with INmune Bio Inc.aligns perfectly with our mission to pioneer innovative stem cell exosome products. Their understanding of efficient human stem cell isolation and large-scale manufacturing provides us with a remarkable opportunity to expand our manufacturing capabilities, expand our product portfolio, and make a significant impact in the market.”
